Denali Therapeutics (DNLI) Total Non-Current Liabilities (2017 - 2025)

Denali Therapeutics (DNLI) has reported Total Non-Current Liabilities for 7 consecutive years, with $123.0 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Total Non-Current Liabilities fell 70.54% year-over-year to $123.0 million; the TTM figure through Dec 2023 stood at $123.0 million (down 70.54% YoY), while the FY2023 annual figure was $123.0 million, down 70.54% from the prior year.
• Total Non-Current Liabilities climbed to $123.0 million in Q4 2023 per DNLI's latest filing, from $118.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $453.0 million in Q4 2020 and bottomed at $118.1 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $289.1 million across 5 years, with a median of $295.0 million in 2020.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 201.41% — and 2023, when it sank 71.61%.
• Denali Therapeutics' Total Non-Current Liabilities stood at $158.0 million in 2019, then surged by 186.81% to $453.0 million in 2020, then fell by 2.55% to $441.5 million in 2021, then decreased by 5.45% to $417.4 million in 2022, then sank by 70.54% to $123.0 million in 2023.
• Business Quant data shows DNLI's Total Non-Current Liabilities at $123.0 million in Q4 2023, $118.1 million in Q3 2023, and $118.5 million in Q2 2023.